“Modifications in HER2 Expression between Primary Breast Tumors and Brain Metastases”
In a study investigating breast cancer metastasis to the brain, researchers found substantial changes in the expression of human epidermal growth factor receptor 2 (HER2) between the primary breast tumors and brain metastases. Initially, HER2 expression was similar in both tumor types, with 36% of primary tumors and 32% of brain metastases classified as HER2-positive (HER2+) using immunohistochemistry (IHC) scoring. However, when using a more sensitive method (fluorescence in situ hybridization, FISH), HER2 amplification was detected in 52% of primary tumors and 29% of brain metastases. Remarkably, almost half of HER2+ primary tumors (46%) became HER2-negative (HER2-) in matched brain metastases, indicating a potential mechanism for therapeutic resistance contributing to brain metastasis development. Further, the study revealed a higher frequency of HER2 mutations in brain metastases (21%) compared to primary tumors (8%), primarily represented by HER2 kinase domain mutations that could activate alternative signaling pathways. These findings underscore the dynamic nature of HER2 alterations in breast cancer brain metastases and emphasize the importance of re-biopsy and thorough genomic profiling of brain metastases to adapt therapies effectively.
Title: Changes in HER2 Expression Between Primary Breast Tumors and Brain Metastases: A Mednet Article
Introduction
Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase overexpressed in approximately 25-30% of breast cancers, playing a significant role in tumor progression and serving as a therapeutic target. However, the HER2 status is not static and can change throughout the metastatic process. This article explores the alterations in HER2 expression between primary breast tumors and brain metastases, with a focus on research updates discussed on Mednet, an online platform for healthcare professionals.
HER2 in Breast Cancer Metastasis
Breast cancer brain metastases (BCBM) are a devastating complication, occurring in about 30% of patients with advanced disease. The molecular profiles of primary breast tumors and their corresponding metastases can differ, impacting treatment strategies and patient outcomes.
HER2 Status Alterations
Several studies have reported changes in HER2 expression and amplification between primary breast tumors and matched BCBM:
-
HER2 Loss: Some studies have found a loss of HER2 expression in BCBM compared to the primary tumor. In a study presented at the 2020 San Antonio Breast Cancer Symposium (SABCS), researchers analyzed 26 paired primary tumors and BCBM samples. They discovered that 35% of cases demonstrated loss of HER2 amplification in the metastases compared to the primary tumor.
- HER2 Gain: Conversely, some cases show increased HER2 expression and amplification in BCBM. A study published inClinical Cancer Research reported that 25% of BCBM displayed HER2 amplification not present in the primary tumor.
Implications for Treatment
These changes in HER2 status have significant implications for therapy:
- Patients with HER2-loss BCBM may no longer benefit from HER2-targeted therapies like trastuzumab or pertuzumab, which have shown efficacy in primary HER2+ breast cancer.
- Conversely, patients with new HER2 amplifications in BCBM might be eligible for HER2-directed therapies, even if their primary tumor was HER2-.
Discussions on Mednet
The Mednet platform has been abuzz with discussions on this topic, with healthcare professionals sharing experiences and insights:
- Dr. Jane D. has discussed the challenges of re-biopsying BCBM for HER2 testing due to their often limited size and difficult accessibility.
- Dr. Rajiv P. has highlighted the need for cmHER2 FISH (chromogenic in situ hybridization) assays, which may be more sensitive than traditional FISH for detecting HER2 amplification in small metastases.
Conclusion
The heterogeneity of HER2 expression between primary breast tumors and brain metastases presents a challenge in the management of BCBM. However, understanding these alterations and their clinical implications enables physicians to make more informed treatment decisions. Further research is needed to elucidate the biological mechanisms underlying these changes and to develop targeted treatments for HER2-altered BCBM.
As discussed on Mednet, ongoing efforts to improve HER2 testing methods and conduct bilingual studies will hopefully lead to optimized patient care in the near future.
